Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Kunshan RiboQuark Raises $7.5 Million for siRNA Projects

publication date: Jan 10, 2014
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Kunshan RiboQuark Pharma, a siRNA joint venture formed by Suzhou Ribo Life Science and Quark Pharma of California, raised almost 45 million RMB ($7.5 million) in a series A round. The financing was led by BVCF, formerly known as BioVeda China. RiboQuark will use the money to further clinical development of QPI-1007, a siRNA ocular neuroprotectant developed by Quark for which the JV owns China rights. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors